PBMC-Humanized Models for Targeted Cancer Immunotherapy

Monoclonal antibodies and checkpoint inhibitors have achieved remarkable clinical success in cancer immunotherapy. Two bispecific antibodies, catumaxomab and blinatumomab, have also been approved to treat cancer patients, and many more are currently in preclinical or clinical development.